Browse the evidence

GLP‐1RAs triggered more gastrointestinal adverse events than placebo, with no in‐between difference.

Clinicians should be aware of the gastrointestinal side effects associated with GLP-1RAs when prescribing these medications.

The prevalence of obesity among primary care patients increased from 39.2% in 2017 to 40.7% in 2019.

Healthcare providers should be aware of the rising obesity rates among their patients.

Nonalcoholic fatty liver disease (NAFLD) affects more than 25% of adults worldwide.

Healthcare providers should be aware of the high prevalence of NAFLD in adult populations.

The majority of patients with NAFLD are unaware of their condition.

Awareness and screening for NAFLD should be prioritized in clinical practice.

There is no consensus definition of sarcopenia despite its evolving criteria.

Practitioners should be aware of the lack of consensus in defining sarcopenia when diagnosing and treating patients.

Overall relative search volume (RSV) for 'Ozempic' grew exponentially in the United States between March 2018 and February 2023.

Practitioners should be aware of the increasing public interest in Ozempic for weight loss.

Statistically significant differences in search popularity were found between 'Ozempic', 'Wegovy', and 'Mounjaro' from December 2021 to February 2023.

Surgeons should consider the varying popularity of these medications in their practice.

In 2018, the mean global intake per person of unprocessed red meat was 51 g/day, with 17 countries having mean intakes of at least one serving (100 g) per day.

Practitioners should be aware of the significant global consumption of unprocessed red meat and target interventions accordingly.

Between 1990 and 2018, global intakes of unprocessed red meat, eggs, milk, processed meat, seafood, and cheese increased.

This trend indicates a growing consumption of certain animal-source foods, which may have implications for public health and nutrition policies.

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is projected to increase from 33.7% (86.3 million people) in 2020 to 41.4% (121.9 million people) by 2050.

Health systems should prepare for a significant increase in MASLD cases.

Cases of metabolic dysfunction-associated steatohepatitis (MASH) are expected to rise from 14.9 million (5.8% of US adults) in 2020 to 23.2 million (7.9% of US adults) by 2050.

Increased awareness and management strategies for MASH are needed.

Liver-related mortality is estimated to increase from 30,500 deaths (1.0% of all-cause deaths in adults) in 2020 to 95,300 deaths (2.4%) in 2050.

Strategies to reduce liver-related mortality must be prioritized.

There is a need for the development of highly efficacious and safe new agents for obesity treatment.

Healthcare providers should advocate for and support the development of new obesity treatments.

The FDA-approved label for resmetirom does not require liver biopsy to confirm the diagnosis of fibrotic MASH.

Clinicians can diagnose fibrotic MASH without the need for invasive liver biopsy, simplifying patient assessment.

Substituting water for SSBs was not associated with any outcome.

Practitioners should note that water substitution does not yield measurable benefits in this context.

There are significant research disparities in the data available on Asian American adults in risk prediction models, national surveillance surveys, and clinical trials.

More inclusive research efforts are needed to address health disparities in Asian American populations.

SCD1 inhibitors have been developed to treat various types of cancer.

SCD1 inhibitors could be a promising avenue for cancer therapy.

Significant disproportionality was detected for semaglutide-associated suicidal ideation (ROR, 1.45; 95% CI, 1.18-1.77; IC, 0.53; 95% CI, 0.19-0.78).

Clinicians should be aware of the potential risk of suicidal ideation in patients treated with semaglutide.

A total of 107 cases of suicidal and/or self-injurious ADRs were reported with semaglutide.

Awareness of the number of reported cases can inform risk assessments for semaglutide use.

GLP1-RA treatment is not associated with a significant difference in risk of serious psychiatric adverse events compared with placebo (log[RR] = -0.02; P = .87).

GLP1-RAs can be considered safe regarding serious psychiatric events in this population.

There is a lack of data in female animal models or women regarding GLP-1 research.

More research is needed in female populations to understand GLP-1 effects.

There were no between-group differences in body composition and adaptive thermogenesis.

Practitioners should note that both diets did not significantly affect body composition or thermogenesis.

There were no reported hospitalizations from severe hypoglycemia or diabetic ketoacidosis in the treated group.

The safety profile suggests that tirzepatide may be a safe option for managing T1D in this population.

There is a strong correlation between online search trends and prescriptions for semaglutide (Wegovy) with a correlation coefficient of r = 0.97.

Monitoring online search trends can provide insights into public interest in obesity medications.